These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 19527806)
1. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806 [TBL] [Abstract][Full Text] [Related]
2. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000 [TBL] [Abstract][Full Text] [Related]
3. Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Yamamoto M; Yamaguchi T; Yamauchi M; Kaji H; Sugimoto T Calcif Tissue Int; 2007 Jun; 80(6):353-8. PubMed ID: 17549536 [TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G; Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031 [TBL] [Abstract][Full Text] [Related]
5. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770 [TBL] [Abstract][Full Text] [Related]
6. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426 [TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes. Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765 [TBL] [Abstract][Full Text] [Related]
9. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Yamaguchi T; Kanazawa I; Yamamoto M; Kurioka S; Yamauchi M; Yano S; Sugimoto T Bone; 2009 Aug; 45(2):174-9. PubMed ID: 19446053 [TBL] [Abstract][Full Text] [Related]
10. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats. Morsy MA; Ashour OM; Fouad AA; Abdel-Gaber SA Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):173-7. PubMed ID: 19566821 [TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Liapis CD; Alevizos M Diabet Med; 2008 Mar; 25(3):333-40. PubMed ID: 18307460 [TBL] [Abstract][Full Text] [Related]
12. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Vinik AI; Zhang Q Diabetes Care; 2007 Apr; 30(4):795-800. PubMed ID: 17259481 [TBL] [Abstract][Full Text] [Related]
13. Investigation of the relationship between type 2 diabetes and osteoporosis using Bayesian inference. Sta Romana M; Li-Yu JT J Clin Densitom; 2007; 10(4):386-90. PubMed ID: 17993401 [TBL] [Abstract][Full Text] [Related]
14. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806 [TBL] [Abstract][Full Text] [Related]
15. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967 [TBL] [Abstract][Full Text] [Related]
16. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. Yamamoto M; Yamaguchi T; Yamauchi M; Kaji H; Sugimoto T J Bone Miner Res; 2009 Apr; 24(4):702-9. PubMed ID: 19049338 [TBL] [Abstract][Full Text] [Related]
17. Distal upper and lower limb fractures associated with thiazolidinedione use. Jones SG; Momin SR; Good MW; Shea TK; Patric K Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952 [TBL] [Abstract][Full Text] [Related]
18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976 [TBL] [Abstract][Full Text] [Related]
19. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278 [TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]